Immuno-Oncology

PACT is currently advancing neoTCR-T cell therapies for patients with different types of solid cancers across the range of low to high tumor mutational burdens. Our pipeline of cancer therapies includes investigational therapies and next generation technologies that have the potential to accelerate curative cell therapies for cancer.